Skip to content

Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration

Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04971681
Enrollment
9
Registered
2021-07-21
Start date
2021-10-08
Completion date
2022-06-02
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Brief summary

This will be a single site randomized, 2-session, within-subject cross-over design pilot study. 20 enrolled (of 30 consented) subjects reporting varying levels of binge and high intensity drinking, defined as at least 2 episodes of drinking 4 (for women) or 5 (for men) drinks on an occasion over the last 5 weeks, (unless determined by PI that drinking history meets study objectives), will be enrolled. Subjects will be randomized to undergo one session of repetitive transcranial magnetic stimulation (rTMS) or sham immediately followed by the investigators rate control intravenous (IV) alcohol self-administration (ASA) paradigm. Subjects will then return 7-14 days later and undergo the same sequence of events with the opposite intervention (i.e. rTMS or sham) from session 1.

Detailed description

This pilot study intends to address the critical unmet need to develop novel treatments for alcohol use disorder (AUD), such as repetitive transcranial magnetic stimulation (rTMS), that directly impact drinking behavior. Binge drinking and high intensity drinking, or consumption meeting at least binge criteria, is a high-risk alcohol self-administration (ASA) pattern associated with the binge-intoxication stage of AUD and the rewarding effects of alcohol. The investigators propose to quantify the impact of medial prefrontal cortex (mPFC) rTMS on ASA using the investigators novel rate-control paradigm. The rate control paradigm allows subjects to determine how quickly their breath alcohol concentration (BrAC) will change (increase, decrease, or stay the same) over the next 3-5 minute epoch, at the end of which brief computer-assisted assay of craving for alcohol and subjective response attributed to alcohol's effect on stimulation, sedation, liking and well-being in a manner comparable to the Brief Biphasic Alcohol Effects Scale (BAES). Each assay requires less than 20 seconds to complete and will be administered during the last \ 0.5 minutes of alcohol delivery but before selection of the next rate of exposure. The ensemble provides detailed self-administered time course of alcohol exposure and corresponding time-stamped series of quantified perceptions for analysis. This approach has demonstrated sensitivity in associating self-reported high intensity drinking and the time until a binge alcohol exposure of 80 milligrams per decilitre (mg/dL). The investigators premise is that clinically impactful neuromodulation should change ASA. Coupling rTMS to a laboratory-assessed ASA paradigm could document causal changes in drinking behavior attributable to modulation of specific neural circuits. The goal of this project is to generate preliminary data supporting the investigators central hypothesis - rTMS targeting to the mPFC, a primary cortical input to the frontal-striatal reward (FSR) circuit, will decrease the rate of alcohol self-administration.

Interventions

DEVICELow frequency repetitive transcranial magnetic stimulation (rTMS)

Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses

DEVICESham

The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

1. Overtly healthy men and women aged 21 - 35 2. Able to give informed consent 3. Able to understand/complete questionnaires and procedures in English 4. Willing and able to adhere to the study schedule 5. At least 2 binge drinking events (at least 4 or 5 drinks on a drinking day for women and men respectively over the last 5 weeks, unless determined by study physicians that drinking history meets study objectives 6. Have venous access sufficient to allow blood sampling

Exclusion criteria

1. Pregnant or breast-feeding 2. Desire to be treated for any substance use disorder or court ordered to not drink alcohol 3. Medical disorders or other conditions, such as lifetime history of a seizure, including history of Electroconvulsive therapy (ECT) but excluding febrile seizures and those induced by substance withdrawal, that may influence study outcome or subject safety 4. First degree relative with idiopathic epilepsy or other seizure disorder 5. Diagnostic and Statistical Manual (DSM) 5 Disorders (non-AUD) or current/history of neurological disease of cerebral origin, or head injury with \> 20 min loss of consciousness, if determined by the study physicians to affect subject safety or data integrity 6. Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine if determined by the study physicians to adversely affect subject safety or data integrity 7. Medications (past 30 days) that could influence subject data/subject safety (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by study physicians 8. Positive BrAC reading at beginning of any study session 9. Actively suicidal (for example, any suicide attempts within the past 3 months or any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the study physicians 10. Any condition for which the study physicians determine it is unsafe or not prudent to enroll a subject

Design outcomes

Primary

MeasureTime frameDescription
T8090 minThe amount of time subjects take to self-administer enough alcohol to raise their breath alcohol concentration (BrAC) to 80 mg/dL

Secondary

MeasureTime frameDescription
Alcohol Consumption (Drinks/Week)5 weeksAlcohol consumption as measured by Time Line Follow Back (TLFB) comparing drinking baseline (5 weeks prior to study) with post-treatment during the 5-week follow-up period. The Timeline Follow-back (TLFB) is uses a calendar to assess a subject's retrospective estimates of their daily drinking.

Countries

United States

Participant flow

Recruitment details

Healthy men and women were recruited from past participants consented to be contacted for future studies, through flyers placed on public bulletin boards, and through ads placed in a local emailed jobs list. Minimum criteria included age 21-35 and consumption of at least 4 drinks/day on at least 2 days in a recent 35 day period

Participants by arm

ArmCount
Active rTMS First
Subjects counterbalanced to session order Active rTMS-Sham rTMS
4
Sham rTMS First
Subjects counterbalanced to order Sham rTMS-Active rTMS
5
Total9

Withdrawals & dropouts

PeriodReasonFG000FG001
FollowupLost to Follow-up10

Baseline characteristics

CharacteristicActive rTMS FirstTotalSham rTMS First
Age, Customized
Age 21-35 years
4 Participants9 Participants5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3 Participants8 Participants5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants2 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
4 Participants6 Participants2 Participants
Region of Enrollment
United States
4 participants9 participants5 participants
Sex: Female, Male
Female
3 Participants6 Participants3 Participants
Sex: Female, Male
Male
1 Participants3 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 90 / 9
other
Total, other adverse events
0 / 90 / 9
serious
Total, serious adverse events
0 / 90 / 9

Outcome results

Primary

T80

The amount of time subjects take to self-administer enough alcohol to raise their breath alcohol concentration (BrAC) to 80 mg/dL

Time frame: 90 min

ArmMeasureValue (MEAN)Dispersion
Low Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)T8061.5 MinutesStandard Error 9.4
Sham rTMS StimulationT8071.6 MinutesStandard Error 8
p-value: <0.27t-test, 2 sided
Secondary

Alcohol Consumption (Drinks/Week)

Alcohol consumption as measured by Time Line Follow Back (TLFB) comparing drinking baseline (5 weeks prior to study) with post-treatment during the 5-week follow-up period. The Timeline Follow-back (TLFB) is uses a calendar to assess a subject's retrospective estimates of their daily drinking.

Time frame: 5 weeks

ArmMeasureValue (MEAN)Dispersion
Low Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)Alcohol Consumption (Drinks/Week)14.8 Drinks/weekStandard Error 4.9
Sham rTMS StimulationAlcohol Consumption (Drinks/Week)7.8 Drinks/weekStandard Error 3.5
p-value: <0.1t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026